Publications by authors named "Isabella Carderi"
The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.
View Article and Find Full Text PDFArticle Synopsis
- Treatment of genotype-3 HCV is challenging, and a study aimed to compare real-life outcomes of three antiviral regimens: SOF+DAC, SOF/VEL, and GLE/PIB.
- The study analyzed 2082 patients, finding that overall response rates after 12 weeks were similar across treatments, with SOF/VEL showing better outcomes only when ribavirin was not included in the regimen.
- The findings suggest that there is a shift towards newer, ribavirin-free treatments which could potentially simplify the management of this difficult-to-treat HCV genotype without compromising success rates.
Background: Data on the efficacy of antiviral therapy in patients with HCV-related compensated cirrhosis are generally drawn from analyzing subgroups in larger trials.
Aims: (1) To analyze the safety and efficacy of combination therapy in naive patients with HCV-related cirrhosis; (2) to evaluate the factors influencing the sustained virologic response (SVR) in cirrhotic patients by comparison with a group of noncirrhotic patients; (3) to analyze the outcome of cirrhotic patients either acquiring SVR and nonresponders to the antiviral therapy during the posttreatment follow-up.
Methods: We consecutively enrolled 365 patients with biopsy-proven HCV-related chronic hepatitis meeting the inclusion criteria for pegylated interferon a-2b plus Ribavirin: 87 patients had compensated liver cirrhosis and 278 had histologic stages between 1 and 4 according to Ishak's classification.
Purpose: An elevated frequency of the CCR5-Delta32 mutation in German patients with hepatitis C with viremia has been reported. The aim of the present study was to verify whether this mutation occurs in an Italian population with hepatitis C and whether it is an adverse host factor indicative of severity of liver disease and response to antiviral therapy.
Study: The authors amplified 189-bp (wild-type) and 157-bp (Delta32 deletion) fragments of the CCR5 gene by polymerase chain reaction in 130 patients with chronic hepatitis C.
A single nucleotide polymorphism characterized by the substitution of valine for glutamate (V1188E) in exon 25 of the multidrug resistance protein 2 gene was found in a group of patients with primary biliary cirrhosis. This heterozygous mutation was significantly associated with the presence of pruritus.
View Article and Find Full Text PDFUnlabelled: Autoimmune hepatitis/primary sclerosing cholangitis (AIH/PSC) overlap syndrome is a relatively uncommon variant of PSC.
Aim: To evaluate the natural history of AIH/PSC overlap syndrome compared to a group of "classical" PSC.
Methods: Forty-one consecutive PSC patients, with a regular follow-up of at least 2 years, were prospectively included in the study.